TERT and pulmonary fibrosis: The group established a progressive lung fibrosis model in TERT−/− TG mice by treating them with low doses of bleomycin (0.5 mg/kg) to closely recapitulate the molecular pathogenesis of clinical IPF, involving both continuous damage and telomere shortening [43].